Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Oxford BioMedica
Oxford BioMedica
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Pharmaceutical
UK vaccine manufacturing nonprofit signs first industry partnership
Oxford Biomedica will be collaborating with VMIC to enable scaled-up manufacture of viral vector-based vaccines
Hi Tech Manufacturing
Oxford Biomedica partners with Microsoft to improve yield of gene therapy via machine learning
Collaboration will see the computing expert develop in silico models and algorithms to address the manufacturing challenges of novel therapies
Recruitment
CGT Catapult addresses skills gap with apprenticeship programme for advanced therapies
Programme will address the projected skills shortage facing public and private employers in the growing cell and gene therapy sector
Design & Build
Oxford BioMedica receives MHRA GMP manufacturing approvals
For lentiviral gene therapy bioprocessing and process development
Design & Build
WHP completes bio-manufacturing facility for Oxford BioMedica
Additional cleanroom space took less than 12 months from concept to completion and creates extra capacity
Manufacturing
Dr Paul Blake becomes Chief Development Officer at Oxford BioMedica
Will take responsibility for the clinical development of pipeline of gene and cell therapies
Research & Development
UK biotechs win Biomedical Catalyst funding of almost £100m
Thirty-three UK companies have received business-led awards
Subscribe now